Astria Therapeutics, Inc.

Equities

ATXS

US04635X1028

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
9.54 ^USD	+1.17%		-1.95%	+24.22%

May. 09	Astria Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 23	HC Wainwright Cuts Astria Therapeutics' Price Target to $16 From $18, Maintains Buy Rating	MT

Catabasis Pharmaceuticals, Inc. Appoints Noah Clauser as Chief Financial Officer

September 21, 2020 at 08:10 am EDT

On September 17, 2020, the Board of Directors of Catabasis Pharmaceuticals, Inc. appointed Noah Clauser to the position of Chief Financial Officer of the company, effective immediately. Prior to his appointment, Mr. Clauser had served as the company's Vice President, Finance since August 2017, leading the company's finance and operations functions.

Latest news about Astria Therapeutics, Inc.

Astria Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
HC Wainwright Cuts Astria Therapeutics' Price Target to $16 From $18, Maintains Buy Rating	Apr. 23	MT
Astria Therapeutics, Inc. Appoints Sunil Agarwal to the Board of Directors and Member of the Science and Technology Committee	Apr. 09	CI
Wedbush Raises Astria Therapeutics' PT to $22 From $17 After Reporting Top-Line Phase 1/2 ALPHA-STAR Results for STAR-0215 Program; Maintains Outperform Rating	Mar. 26	MT
Transcript : Astria Therapeutics, Inc. - Special Call	Mar. 25
Astria Therapeutics, Inc. Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE	Mar. 25	CI
North American Morning Briefing : Markets on Hold -2-	Mar. 20	DJ
Astria Therapeutics, Inc.(NasdaqGM:ATXS) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
Certain Stock Options of Astria Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAR-2024.	Mar. 15	CI
Certain Common Stock of Astria Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAR-2024.	Mar. 15	CI
Astria Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 04	CI
Astria Therapeutics Shares Rise After Pricing of $125 Million Underwritten Offering	Jan. 30	MT
Astria Therapeutics Files $500 Million Mixed Shelf	Dec. 15	MT
Oppenheimer Adjusts Astria Therapeutics Price Target to $25 From $30, Maintains Outperform Rating	Nov. 15	MT
Wedbush Trims Astria Therapeutics' Price Target to $17 From $18, Keeps Outperform Rating	Nov. 13	MT
Transcript : Astria Therapeutics, Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Astria Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
North American Morning Briefing : Stock Futures Dip as Inflation Data Looms	Nov. 13	DJ
Astria Therapeutics, Inc. Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting	Nov. 10	CI
Wedbush Adjusts Price Target on Astria Therapeutics to $18 From $25, Maintains Outperform Rating	23-10-13	MT
Transcript : Astria Therapeutics, Inc. - Special Call	23-10-12
HC Wainwright Adjusts Astria Therapeutics Price Target to $18 From $20, Maintains Buy Rating	23-10-12	MT
Indian Equities End Lower on Profit Booking; IT Tops Laggards	23-10-12	MT
Astria Therapeutics Prices Common Stock, Warrants Offering for Expected Gross Proceeds of About $64 Million	23-10-12	MT
Glenmark Pharma Unit Licenses Antibody Portfolio to Astria Therapeutics	23-10-12	MT

Chart Astria Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.

Sector

Biotechnology & Medical Research

Calendar

2024-06-05 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.54 USD

Average target price

25.29 USD

Spread / Average Target

+165.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ASTRIA THERAPEUTICS, INC.	+24.22%	524M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs